Enanta/$ENTA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Enanta
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
- Ticker
- $ENTA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 120
- Headquarters
- Watertown, United States
- Website
- www.enanta.com
Enanta Metrics
BasicAdvanced
$393m
-
-$2.34
0.93
-
Price and volume
Market cap
$393m
Beta
0.93
52-week high
$17.15
52-week low
$6.60
Average daily volume
173k
Financial strength
Current ratio
3.759
Quick ratio
3.619
Long term debt to equity
139.856
Total debt to equity
180.116
Interest coverage (TTM)
-4.55%
Profitability
EBITDA (TTM)
-53.816
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-96.89%
Operating margin (TTM)
-89.99%
Effective tax rate (TTM)
-0.16%
Revenue per employee (TTM)
$540,000
Management effectiveness
Return on assets (TTM)
-12.28%
Return on equity (TTM)
-70.12%
Valuation
Price to revenue (TTM)
5.599
Price to book
3.89
Price to tangible book (TTM)
3.89
Growth
Revenue change (TTM)
0.70%
Earnings per share change (TTM)
-45.82%
3-year revenue growth (CAGR)
-6.79%
10-year revenue growth (CAGR)
-3.15%
3-year earnings per share growth (CAGR)
-28.18%
10-year earnings per share growth (CAGR)
4.47%
What the Analysts think about Enanta
Analyst ratings (Buy, Hold, Sell) for Enanta stock.
Enanta Financial Performance
Revenues and expenses
Enanta Earnings Performance
Company profitability
Enanta News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.